Passage Bio, Inc. (NASDAQ:PASG – Get Free Report) major shareholder Lynx1 Capital Management Lp acquired 373,645 shares of the stock in a transaction dated Friday, December 27th. The stock was bought at an average price of $0.65 per share, with a total value of $242,869.25. Following the purchase, the insider now directly owns 9,256,953 shares in the company, valued at $6,017,019.45. This represents a 4.21 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Lynx1 Capital Management Lp also recently made the following trade(s):
- On Wednesday, November 27th, Lynx1 Capital Management Lp purchased 29,300 shares of Passage Bio stock. The stock was bought at an average price of $0.67 per share, with a total value of $19,631.00.
- On Monday, November 25th, Lynx1 Capital Management Lp acquired 259,998 shares of Passage Bio stock. The shares were bought at an average price of $0.56 per share, for a total transaction of $145,598.88.
Passage Bio Stock Performance
PASG stock opened at $0.83 on Friday. The business has a 50-day simple moving average of $0.67 and a two-hundred day simple moving average of $0.74. The company has a market capitalization of $51.27 million, a P/E ratio of -0.71 and a beta of 1.43. Passage Bio, Inc. has a 52-week low of $0.45 and a 52-week high of $1.79.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
A number of analysts recently commented on the company. Wedbush began coverage on Passage Bio in a research report on Friday, November 29th. They issued an “outperform” rating and a $4.00 target price for the company. Canaccord Genuity Group restated a “buy” rating and set a $13.00 price objective on shares of Passage Bio in a report on Thursday, November 14th. Finally, Chardan Capital reiterated a “buy” rating and issued a $7.00 target price on shares of Passage Bio in a report on Thursday, November 14th.
Check Out Our Latest Stock Analysis on Passage Bio
Passage Bio Company Profile
Passage Bio, Inc, a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.
Recommended Stories
- Five stocks we like better than Passage Bio
- What is Put Option Volume?
- 3 Legacy Tech Companies Reemerging as AI Leaders
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.